MAFLD and chronic kidney disease: two sides of the same coin?

Ziyan Pan¹, Saleh A Alqahtani^{2

3}, Mohammed Eslam⁴

Affiliations

¹ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, 2145, Australia.
² Liver Transplant Center, King Faisal Specialist Hospital and Research Center, Riyadh, 12713, Saudi Arabia.
³ Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
⁴ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, 2145, Australia. mohammed.eslam@sydney.edu.au.

PMID: 37069420
DOI: 10.1007/s12072-023-10526-9

Editorial

MAFLD and chronic kidney disease: two sides of the same coin?

Ziyan Pan et al. Hepatol Int. 2023 Jun.

. 2023 Jun;17(3):519-521.

doi: 10.1007/s12072-023-10526-9. Epub 2023 Apr 17.

Authors

Ziyan Pan¹, Saleh A Alqahtani^{2

3}, Mohammed Eslam⁴

Affiliations

¹ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, 2145, Australia.
² Liver Transplant Center, King Faisal Specialist Hospital and Research Center, Riyadh, 12713, Saudi Arabia.
³ Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
⁴ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW, 2145, Australia. mohammed.eslam@sydney.edu.au.

PMID: 37069420
DOI: 10.1007/s12072-023-10526-9

No abstract available

PubMed Disclaimer

Comment on

Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants.
Chen S, Pang J, Huang R, Xue H, Chen X. Chen S, et al. Hepatol Int. 2023 Jun;17(3):595-605. doi: 10.1007/s12072-023-10486-0. Epub 2023 Feb 21. Hepatol Int. 2023. PMID: 36809487

Cited by

Developing and validating a predictive model for all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease.
Zhang F, Liu L, Li W. Zhang F, et al. Diabetol Metab Syndr. 2025 May 20;17(1):161. doi: 10.1186/s13098-025-01724-6. Diabetol Metab Syndr. 2025. PMID: 40394710 Free PMC article.
Liver-Kidney Crosstalk in Major Pediatric Diseases: Unraveling the Complexities and Clinical Challenges.
Piatto D, De Biasio D, Cesaro FG, Forcina G, Frattolillo V, Colucci A, Lamberti F, Marzuillo P, Miraglia Del Giudice E, Di Sessa A. Piatto D, et al. J Clin Med. 2025 Jun 2;14(11):3911. doi: 10.3390/jcm14113911. J Clin Med. 2025. PMID: 40507673 Free PMC article. Review.
Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study.
Cen C, Fan Z, Ding X, Tu X, Liu Y. Cen C, et al. Sci Rep. 2024 Jun 2;14(1):12645. doi: 10.1038/s41598-024-63386-0. Sci Rep. 2024. PMID: 38825630 Free PMC article.
Comparative associations of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease with risk of incident chronic kidney disease: a cohort study.
Heo JH, Lee MY, Kim SH, Zheng MH, Byrne CD, Targher G, Sung KC. Heo JH, et al. Hepatobiliary Surg Nutr. 2024 Oct 1;13(5):801-813. doi: 10.21037/hbsn-23-558. Epub 2024 Jun 14. Hepatobiliary Surg Nutr. 2024. PMID: 39507738 Free PMC article.
Effects of MAFLD defined by fatty liver index or ultrasonography on kidney function decline in the general population.
Lee YJ, Kim KM, Ko NG, Jin M, Na JH, Park IH. Lee YJ, et al. Sci Rep. 2024 Sep 11;14(1):21189. doi: 10.1038/s41598-024-72482-0. Sci Rep. 2024. PMID: 39261554 Free PMC article.

References

1. Wang T-Y, Wang R-F, Bu Z-Y, Targher G, Byrne CD, Sun D-Q, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18:259–268 - DOI - PubMed
1. Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic associated fatty liver disease. A meta-analysis and systematic review of 10,739,607 individuals. J Clin Endocrinol Metab. 2022. https://doi.org/10.1210/clinem/dgac321 - DOI - PubMed - PMC
1. Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022. https://doi.org/10.1038/s41575-022-00635-5 - DOI - PubMed
1. Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38:251–260 - DOI - PubMed
1. Eslam M, Sarin SK, Wong VW-S, Fan J-G, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919 - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

MAFLD and chronic kidney disease: two sides of the same coin?

Affiliations

MAFLD and chronic kidney disease: two sides of the same coin?

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical